QBiotics is a public unlisted Australian life sciences company that discovers and develops novel cell signalling small molecules. Our current clinical focus is the treatment of solid tumours, and debilitating chronic wounds. QBiotics anticancer lead, tigilanol tiglate, is an intratumoral, oncolytic small molecule that has potential in the treatment of a range of solid tumors, either as a monotherapy, or in combination with checkpoint inhibitors, conventional chemotherapy and/or radiotherapy. Tigilanol tiglate is currently in clinical Phase II development for the treatment of soft tissue sarcomas in the USA (recently awarded Orphan Drug Designation) and head and neck cancers in the UK and Australia. QBiotics’ wound healing lead, EBC-1013, is a topically applied small molecule for treatment of a wide range of chronic and acute wounds and burns. EBC-1013 is soon to enter a first-in-human clinical Phase I/II safety trial in patients with venous leg ulcers.